Companion diagnostics are now an essential part of a new drug launch. Patient stratification is key to successful trials, approval, and patient welfare. But developing a companion diagnostic along with a drug is a challenge. -- Dr. Joe Krueger, Astellas
Flagstaff, AZ (PRWEB) July 6, 2010
Flagship Biosciences LLC, a provider of digital pathology services, announced it has expanded its partnership with Vitro Molecular in Miami, Florida, to provide validated IHC companion diagnostic development capabilities. Vitro Molecular is a physician-owned, anatomic pathology specialty laboratory founded by Hadi Yaziji M.D. in 2007. Vitro provides routine and specialty anatomic pathology services to a loyal physician clientele in Florida and other States. The laboratory is well known for its excellence in histopathology, particularly IHC and other molecular tests. “Our pharmaceutical customers require a scalable histology operation with high levels of excellence and experience in immunohistochemistry,” said David Young, cofounder and president of Flagship Biosciences. “Quantitative image analysis techniques are strongly dependent on reproducible procedures in histology, and Dr. Hadi Yaziji and his team at Vitro Molecular have established themselves as leaders in high quality IHC testing. Dr. Yaziji’s strength in immunohistochemistry techniques, as demonstrated in his leadership of the Annual International Retreats on Applied Immunohistochemistry and Molecular Pathology, will be helpful to Flagship as we look to improve the reproducibility of molecular tissue-based testing.”
“We recognize the importance of whole slide analysis and computer histology pattern recognition in improving immunohistochemistry techniques. We are delighted to partner with Flagship Biosciences in working to ensure that their novel image analysis techniques utilize the best and most reproducible and scalable immunohistochemistry services,” stated Dr. Hadi Yaziji, founder and president of Vitro Molecular.
Flagship Biosciences LLC is a pathologist-owned company focused on utilizing whole slide scanning for quantitative pathology in pharmaceutical and device applications. An recent example of Flagship’s capabilities in companion diagnostics development of multiple IHC markers is their pathologists' work in the development of an epithelial-mesenchymal transition diagnostic test.
# # #